What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Psychiatry
- Statistics
Psychiatry, Internal medicine, Antipsychotic, Schizophrenia and Olanzapine are his primary areas of study.
His research in Psychiatry intersects with topics in Meta-analysis and Randomized controlled trial.
His Internal medicine study combines topics in areas such as Relapse prevention, Placebo, Ziprasidone and Mania.
His work is dedicated to discovering how Antipsychotic, Clinical trial are connected with Cognition, Psychotherapist and Health services research and other disciplines.
His Schizophrenia study combines topics from a wide range of disciplines, such as Psychosis, Severity of illness and Psychometrics.
His Olanzapine study incorporates themes from Quetiapine and Haloperidol.
His most cited work include:
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis (1464 citations)
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis (1384 citations)
- Physical illness in patients with severe mental disorders.I. Prevalence, impact of medications and disparities in health care (1300 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Psychiatry, Internal medicine, Antipsychotic, Schizophrenia and Meta-analysis.
In his research, Cognition is intimately related to Clinical psychology, which falls under the overarching field of Psychiatry.
The various areas that Stefan Leucht examines in his Internal medicine study include Placebo and Olanzapine.
His work carried out in the field of Olanzapine brings together such families of science as Quetiapine, Risperidone and Aripiprazole.
His Antipsychotic research is multidisciplinary, incorporating elements of Discontinuation, Haloperidol, Relapse prevention, Number needed to treat and Pharmacology.
His Schizophrenia research integrates issues from Psychosis, Medical prescription and Rating scale.
He most often published in these fields:
- Psychiatry (54.99%)
- Internal medicine (37.92%)
- Antipsychotic (36.36%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (37.92%)
- Antipsychotic (36.36%)
- Schizophrenia (32.37%)
In recent papers he was focusing on the following fields of study:
Stefan Leucht mostly deals with Internal medicine, Antipsychotic, Schizophrenia, Meta-analysis and Randomized controlled trial.
He has included themes like Placebo, Psychosis, Positive and Negative Syndrome Scale and Clozapine in his Internal medicine study.
The Antipsychotic study combines topics in areas such as Olanzapine, Reduction and Confidence interval.
His research integrates issues of Dopamine, Neuroscience and Rating scale in his study of Schizophrenia.
His work deals with themes such as Psychological intervention, Psychiatry, Bioinformatics, Tolerability and Fluoxetine, which intersect with Meta-analysis.
His Text mining research extends to Psychiatry, which is thematically connected.
Between 2018 and 2021, his most popular works were:
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis (231 citations)
- Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis (59 citations)
- Specific Substantial Dysconnectivity in Schizophrenia: A Transdiagnostic Multimodal Meta-analysis of Resting-State Functional and Structural Magnetic Resonance Imaging Studies. (34 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Statistics
- Major depressive disorder
Stefan Leucht spends much of his time researching Internal medicine, Meta-analysis, Antipsychotic, Randomized controlled trial and Schizophrenia.
His studies deal with areas such as Risperidone, Placebo and Psychosis, Positive and Negative Syndrome Scale as well as Internal medicine.
His Meta-analysis research incorporates themes from Clinical trial, Schizophrenia, Psychiatry, Fluoxetine and Sertraline.
He studies Antipsychotic, namely Amisulpride.
His Randomized controlled trial research is multidisciplinary, incorporating elements of Quetiapine, Major depressive disorder and Brief Psychiatric Rating Scale.
The concepts of his Schizophrenia study are interwoven with issues in Endocrinology, Effects of sleep deprivation on cognitive performance, Striatum and Dihydroxyphenylalanine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
